Entrar/Registro  
HOME SPANISH
 
Cirugía y Cirujanos
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Cirugía y Cirujanos >Year 2010, Issue 1


Borrayo-Sánchez G, Pacheco-Bouthillier A, Mendoza-Valdez L, Isordia-Salas I, Argüero-Sánchez R, Careaga RG
Valor pronóstico de los niveles de interleucina-6 en pacientes con infarto agudo del miocardio con elevación del segmento ST
Cir Cir 2010; 78 (1)

Language: Español
References: 34
Page: 23-30
PDF: 200.20 Kb.


Full text




ABSTRACT

Background: Interleukin-6 (IL6) plays a role in atherogenesis as well as in most atherothrombotic phenomenon such as the ST-segment elevation acute myocardial infarction (STEAMI). Our objective was to evaluate serum levels of IL6 as prognostic value for major clinical in-hospital events in patients with STEAMI.
Methods: We studied consecutive patients with diagnosis of STEAMI according to ACC/AHA/ESC criteria. Twenty four hours after the acute event, IL6 was determined by chemoluminescence method. The major cardiovascular end point was arrhythmias, angina, heart failure, reinfarction and death.
Results: Included were 97 patients. The level of IL6 to identify high-risk patients was 20 pg/ml. Forty six patients had ‹ 20 pg/ml (group I), and 51 patients had ›20 pg/ml (group II). Mean value of IL6 was 11.52 ± 4.83 pg/ml vs. 63.19 ± 44.4 pg/ml (p ‹ 0.0001). Death was more frequent (2.2 vs. 15.7%, p = 0.023, RR 1.16 95% CI 1.02-1.31) and the end point combined during hospitalization in group II was 21.7 vs. 51% (p = 0.003 RR 1.59 95% CI 1.16-2.19). Multivariate logistic regression analysis identified Killip class ≥2 and IL6 levels ≥20 pg/ml as predictors for in-hospital end point.
Conclusions: Serum levels of IL6 ›20 pg/ml in the first 24 h after STEAMI were significantly associated with higher frequency of in-hospital outcomes such as arrhythmias and death.


Key words: Acute myocardial infarction, interleukin-6.


REFERENCIAS

  1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-372.

  2. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.

  3. Muntaner J, Badimon J, Piredda, A. Placa y sangre vulnerable. Rev CONAREC 2006;86:176-182.

  4. Burke A, Virmani R. Pathophysiology of acute myocardial infarction. Med Clin North Am 2007;91:553-572.

  5. Amstrong E, Morrow D, Sabatine M. Inflammatory biomarkers in acute coronary syndromes. I: Introduction and cytokines. Circulation 2006;113:e72-e75.

  6. Amstrong E, Morrow D, Sabatine M. Inflammatory biomarkers in acute coronary syndromes. II: Acute phase reactant and biomarkers of endothelial cell activation. Circulation 2006;113:e152-e155.

  7. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.

  8. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-1896.

  9. Levi M, Van der Poll T, Büller H. Bidirectional relation between inflammation and coagulation. Circulation 2004;109;2698-2700.

  10. Kerr R. Interleukin 6 and haemostasis. Br J Haematol 2001;115:3-12.

  11. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient. A call for new definitions and risk assessment strategies. II. Circulation 2003;108:1772-1778.

  12. Schwartz RS, Bayes-Genis A, Lesser LR, Sangiorgi M, Henry TD, Conover CA. Detecting vulnerable plaque using peripheral blood: inflammatory and cellular markers. J Interv Cardiol 2003;16:231-242.

  13. James SK, Lindahl B, Siegbahn A, Siegbahn A, Stridsberg M, Venge P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies to Open Occluded Arteries (GUSTO)-IV substudy. Circulation 2003;108:275-281. IL6 en infarto agudo del miocardio

  14. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease. JAMA 2001;286:2107 -2113.

  15. Hartford M, Wiklund O, Mattsson Hultén L, Perers E, Person A, Herlitz J, et al. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int J Cardiol 2006;108:55-62.

  16. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: a consensus of the document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-969.

  17. Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal Definition of Myocardial Infarction. Circulation 2007;116;2634-2653.

  18. Vitale C, Gebara O, Mercuro G, Wajngarten M, Silvestri A, Rossini P, et al. Value of C-reactive protein levels and IL6 in predicting levels in women at increased cardiovascular risk. Maturitas 2005;50:239-246.

  19. Ueda K, Takahashi M, Ozawa K, Kinoshita M. Decreased soluble interleukin-6 receptor in patients with acute myocardial infarction. Am Heart J 1999;138:S327-S416.

  20. Koukkunen H, Penttila K, Kemppainen A, Halinen M, Penttila I, Rantanen T, et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-a in the prognostic classification of unstable angina pectoris. Ann Med 2001;33:37-47.

  21. Ziakas A, Gavrilidis S, Souliou E, Giannoglou G, Stiliadis I, Karvounis H, et al. Ceruloplasmin is a better predictor of the long-term prognosis compared with fibrinogen, CRP, and IL6 in patients with severe unstable angina. Angiology 2009;60:50-59.

  22. Kucharz EJ, Wilk T. Dynamics of serum interleukin-6 level in patients with acute myocardial infarction. Eur J Intern Med 2000;115:253-256.

  23. Biasucci L, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996;94:874-877.

  24. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967;20:457-464.

  25. Ziakas A, Gavrilidis S, Giannoglou G, Souliou E, Gemitzis K, Kalampalika D, et al. In-hospital and long-term prognostic value of fibrinogen, CRP, and IL6 levels in patients with acute myocardial infarction treated with thrombolysis. Angiology 2006;57:283-293.

  26. Bonvini R, Hendiri T, Camenzind E. Inflammatory response postmyocardial infarction and reperfusion: a new therapeutic target? Eur Heart J 2005;7(suppl 1):127-136.

  27. James SK, Lindahl B, Timmer JR, Ottervanger JP, Siegbahn A, Stridsberg M, et al. Usefulness of biomarkers for predicting longterm mortality in patients with diabetes mellitus and non-ST elevation acute coronary syndromes (a GUSTO IV substudy). Am J Cardiol 2006;97:167-172.

  28. Souza JR, Oliveira RT, Blotta MH, Coelho OR. Serum levels of interleukin-6 (II-6), interlukin-18 (II-18) and C-reactive protein (CRP) in patients with type-2 diabetes and acute coronary syndrome without ST-segment elevation. Arq Bras Cardiol 2008;90:86-90.

  29. Deepa R, Velmurugan K, Arvind K, Sivaram P, Sientay C, Uday S, et al. Serum levels of interleukin-6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance-the Chennai Urban Rural Epidemiology Study (CURES). Metabolism 2006;55:1232-1238.

  30. Rieusset J, Bouzakri K, Chevillotte E, Ricard N, Jacquet D, Bastard JP, et al. Suppressor of cytocine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 2004;53:2232-2241.

  31. Klover PJ, Clementi AH, Mooney Ra. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005;146:3417-3427.

  32. Choi KM, Lee KW, Kim SG, Kim NH, Park CG, Seo HS, et al. Inflammation, insulin resistance, and glucose intolerance in acute myocardial infarction patients without a previous diagnosis of diabetes mellitus. J Clin Endocrinol Metab 2005;90:175-180.

  33. Hedman A, Larsson PT, Alam M, Wallen NH, Nordiander R, Samad BA. CPR, IL6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events? Int J Cardiol 2007;120:108-114.

  34. Tan J, Hua Q, Gao J, Fan ZX. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol 2008;31:413-418.






>Journals >Cirugía y Cirujanos >Year 2010, Issue 1
 

· Journal Index 
· Links 






       
Copyright 2019